Second Sight Medical Products Inc
EYESW · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.05 | 0.01 | 0.00 |
| FCF Yield | -39.83% | -62.23% | -39.69% | -168.00% |
| EV / EBITDA | -4.28 | -3.33 | -2.89 | -0.68 |
| Quality | ||||
| ROIC | -34.31% | -31.72% | -21.45% | -62.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.33 | 0.77 | 0.82 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 35.49% | -56.81% | 74.55% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -2.33 | -1.58 | -0.90 | -0.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -5,419.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -565,615.38 |